Tuesday, November 27, 2012 11:21:13 AM
It would seem to me that ARNA will have to prove themselves with good enrollment figures to finally get these sophisticated shorts off their back. Lot of powerful people involved, but no matter, revenue trumps all. I keep thinking how wrong the shorts were in their determination of Belviq approval. Also, Eisai is willing to pay out 200 million to us based on 250 Million in sales. 65 million as soon as DEA classification. Eisai paying 90% of post approval trial expenses for heart valve studies and 50% expenses for pediactric studies. This is a company that knows the science envolved, knows the market and thinks that Belviq will be its most successful drug ever after all those expenses. If you follow the money they also make a strong case and I trust their research over a H.F. and manipulaters anyday. So yes there will be an eventual MOASS. AJMO.
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM
PickleJar Launches National "Get on the Bus" Campaign, Unveils Thompson Square Tour Bus Wrap • PKLE • Sep 4, 2024 7:17 AM